Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis

Int J Pharm Compd. 2016 Jan-Feb;20(1):6-10.

Abstract

Generalized pustular psoriasis is rare in children, but it can occur and affect an extensive body surface area of a child. Treatment regimens can include medications that are not available in pediatric dosage form. Acitretin is considered one of the treatment options for acute generalized pustular psoriasis in children, but, in Singapore, it is only available as Neotigason capsules. Extemporaneous compounding of the powder content in the capsules was developed for formulating the oral acitretin suspension with a standardized formulation table and compounding process at National Skin Centre. An appropriate beyond-use date of the extemporaneous preparation was assigned after reviewing the photostability data of acitretin, compatibility of the active ingredient and excipients, and United States Pharmacopeia <795> guidelines. It is deemed appropriate to assign a beyond-use date of 14 days when the extemporaneous preparation is stored in amber glass bottles at 2 degrees C to 8 degrees C.

Publication types

  • Case Reports

MeSH terms

  • Acitretin / administration & dosage*
  • Acitretin / chemistry
  • Acitretin / therapeutic use
  • Administration, Oral
  • Drug Compounding*
  • Drug Stability
  • Drug Storage
  • Humans
  • Infant
  • Keratolytic Agents / administration & dosage*
  • Keratolytic Agents / chemistry
  • Keratolytic Agents / therapeutic use
  • Male
  • Psoriasis / drug therapy*
  • Psoriasis / pathology
  • Singapore
  • Suspensions

Substances

  • Keratolytic Agents
  • Suspensions
  • Acitretin